Mattia D'agostino
Turin, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 27, 2026
Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.
Journal: Frontiers in oncology
Published: March 03, 2026
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.
Journal: HemaSphere
Published: June 16, 2025
Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Journal: Experimental hematology & oncology
Published: June 13, 2025
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Journal: Nature genetics
Published: June 09, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 09, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.
Journal: Blood
Published: June 03, 2025
Last Updated: 09/26/2026